Vivos Therapeutics, Inc. VVOS 深 沪
已收盘 03-27 16:00:00 美东时间
1.15
-0.040
-3.36%
华盛通- 最 高1.1989
- 今 开1.15
- 成交量 13.44万股
- 最 低 1.11
- 昨 收 1.19
- 总市值 1203.80万
- 52周最高 7.95
- 市盈率 静 --
- 换手率 1.28%
- 52周最低 1.09
- 委 比 49.73%
- 总股本 1046.78万
- 历史最高 360.25
- 量 比 0.96
- 振 幅 7.47%
- 历史最低 1.09
- 每 手 1
- 风险率 1.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
Vivos Therapeutics announced that its Nevada physician-owned practices have achieved 'in-network' status with multiple health insurance payers, including Medicare,TRICARE, and others, significantly improving patient access to its OSA treatments. The company also implemented cost reduction initiatives, including workforce reductions and vendor contract changes, expected to save $4 million annually. These moves aim to reduce cash burn and achieve p...
03-26 12:45
Clinical study links narrower intermolar distance and higher palatal height to obstructive sleep apnea severity
Clinical study links narrower intermolar distance and higher palatal height to obstructive sleep apnea severity Vivos reported findings from a clinical study first published in October 2025 in the Journal of Clinical Medicine that examined the relationship between obstructive sleep apnea (OSA) sever
03-17 20:45
Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy
A recent study published in the *Journal of Clinical Medicine* supports Vivos Therapeutics' belief that specific dental and facial morphologies are directly linked to the severity of obstructive sleep apnea (OSA). The study found that narrower palatal dental arches and higher palatal height are associated with more severe OSA. Vivos CARE devices, FDA-cleared for treating mild to severe OSA in adults and moderate-to-severe OSA in children, work by...
03-17 12:45
Vivos Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Gregg C. Johnson
Vivos Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Gregg C. Johnson Vivos Therapeutics Inc. has filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchange Commission. The filing names Gregg C. Johnson as the beneficial owner, w
02-14 09:37
Vivos Therapeutics Appoints Gregg Johnson to Board
An announcement from Vivos Therapeutics ( ($VVOS) ) is now available. Effective...
02-07 05:38
BUZZ-U.S. STOCKS ON THE MOVE-OneSpaWorld, IMUNON, Cigna
BUZZ-U.S. STOCKS ON THE MOVE-OneSpaWorld, IMUNON, Cigna Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 slid to near two-week lows and the Nasdaq sank to its lowest level
02-05 23:44
Vivos Therapeutics Partners with SoundHealth to Expand Access to Sleep and Allergy Technologies
Vivos Therapeutics Partners with SoundHealth to Expand Access to Sleep and Allergy Technologies Vivos Therapeutics Inc., a leader in medical devices and healthcare services for breathing-related sleep disorders, has announced a collaboration with SoundHealth, a Silicon Valley health technology compa
02-05 21:45
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
The most oversold stocks in the health care sector presents an opportunity to b...
02-03 19:23
Vivos Therapeutics shares are trading lower after the company announced the exercise of warrants generating $4.64 million in gross proceeds.
Vivos Therapeutics shares are trading lower after the company announced the exe...
01-16 21:02
Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds
Vivos Therapeutics, Inc. (VVOS) has entered into a definitive agreement to exercise outstanding warrants to purchase up to 1,982,356 shares at a reduced exercise price of $2.34 per share, generating approximately $4.64 million in gross proceeds. The company will issue new warrants for 3,964,712 shares at $2.09 per share, with varying expiration terms. The offering is expected to close on January 20, 2026, with proceeds used for working capital an...
01-16 13:00
